434 related articles for article (PubMed ID: 29665987)
1. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk W; Le May C; Cariou B
Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
[TBL] [Abstract][Full Text] [Related]
5. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
Lagace TA
Curr Opin Lipidol; 2014 Oct; 25(5):387-93. PubMed ID: 25110901
[TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
8. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
Tavori H; Rashid S; Fazio S
Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
[TBL] [Abstract][Full Text] [Related]
9. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
[TBL] [Abstract][Full Text] [Related]
11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
12. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
13. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
14. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
15. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
Filippatos TD; Kei A; Rizos CV; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
[TBL] [Abstract][Full Text] [Related]
16. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
Kwakernaak AJ; Lambert G; Dullaart RP
Clin Biochem; 2014 May; 47(7-8):679-82. PubMed ID: 24680982
[TBL] [Abstract][Full Text] [Related]
17. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
[No Abstract] [Full Text] [Related]
18. PCSK9 gene mutations and low-density lipoprotein cholesterol.
Wu NQ; Li JJ
Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
20. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
Tavori H; Giunzioni I; Linton MF; Fazio S
Circ Res; 2013 Dec; 113(12):1290-5. PubMed ID: 24122718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
